Prevalence of potential proton-pump inhibitor drug interactions: A retrospective review of prescriptions in community pharmacies

被引:3
|
作者
Saltiel, E [1 ]
Fask, A [1 ]
机构
[1] Cedars Sinai Med Ctr, Managed Care Program, Los Angeles, CA 90035 USA
关键词
omeprazole; lansoprazole; proton-pump inhibitor; drug interactions;
D O I
10.1016/S0149-2918(99)80059-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug interactions are a major cause of drug-related problems. This study assessed the comparative frequency of potential drug-drug interactions,in patients receiving either omeprazole or lansoprazole. We reviewed prescription data from 144 community pharmacies in 25 states for the period of October 12, 1996, through October 20, 1997, from which the rates at which patients received either proton-pump inhibitor concurrently with greater than or equal to 1 potentially interacting drugs were determined. A total of 7306 patients received only omeprazole, and 2486 received only lansoprazole. In this sample, 722 patients (9.9%) who received omeprazole also received a potentially interacting medication at the same time, compared with 8 patients (0.3%) who received lansoprazole (P < 0.001). These data suggest that clinicians should be conscientious when selecting or dispensing drugs for patients taking omeprazole, given the relatively high prevalence of potential drug interactions in clinical practice.
引用
收藏
页码:1812 / 1819
页数:8
相关论文
共 50 条
  • [21] Drug-related problems with new prescriptions - prevalence, nature and management in community pharmacies
    Eichenberger, Patrick M.
    Lampert, Markus L.
    Vogel-Kahmann, Irene
    Mengiardi, Seraina
    van Mil, J. W. Foppe
    Hersberger, Kurt E.
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 668 - 668
  • [22] Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence
    Maes, Marina L.
    Fixen, Danielle R.
    Linnebur, Sunny Anne
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2017, 8 (09) : 273 - 297
  • [23] Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection
    Inghammar, Malin
    Svanstrom, Henrik
    Voldstedlund, Marianne
    Melbye, Mads
    Hviid, Anders
    Molbak, Kare
    Pasternak, Bjorn
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (12) : E1084 - E1089
  • [24] A STUDY OF THE PREVALENCE AND APPROPRIATENESS OF PROTON PUMP INHIBITOR PRESCRIPTIONS IN AN IRISH NURSING HOME COHORT
    Kennedy, Cormac
    Ow, Gavin
    Bourke, Robert
    Fallon, Muireann
    Fitzpatrick, Fidelma
    Martin, Alan
    AGE AND AGEING, 2017, 46
  • [25] Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis
    Lambert, Allison A.
    Lam, Jennifer O.
    Paik, Julie J.
    Ugarte-Gil, Cesar
    Drummond, M. Bradley
    Crowell, Trevor A.
    PLOS ONE, 2015, 10 (06):
  • [26] Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility: A Retrospective Study
    Protopapadakis, Yianni
    Shuster, Hayden
    Bambach, Austin B.
    Fitzgerald, Sean
    Brayman, Christian
    Ewing, Joseph A.
    Blumer, Mary
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (04) : 330 - 336
  • [27] Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999:: cross sectional study
    Merlo, J
    Liedholm, H
    Lindblad, U
    Björck-Linné, A
    Fält, J
    Lindberg, G
    Melander, A
    BRITISH MEDICAL JOURNAL, 2001, 323 (7310): : 427 - 428
  • [28] Proton-pump inhibitor use and risk of community-acquired pneumonia in congenital heart disease patients
    Evers, Patrick D.
    Farkas, Dora K.
    Khoury, Michael
    Olsen, Morten
    Madsen, Nicolas L.
    INTERNATIONAL JOURNAL OF CARDIOLOGY CONGENITAL HEART DISEASE, 2021, 4
  • [29] Proton-Pump Inhibitor Use and Risk of Community-Acquired Pneumonia in Congenital Heart Disease Patients
    Evers, Patrick D.
    Madsen, Nicolas
    Farkas, Dora
    Khoury, Michael
    PEDIATRICS, 2021, 147 (03)
  • [30] Proton pump inhibitor and community pharmacies: Usage profile and factors associated with long-term use
    Lima de Araujo, Lorena Maria
    de Moura Lopes, Maria Vivyanne
    de Arruda, Rafael Silva
    Martins, Rand Randall
    Oliveira, Antonio Gouveia
    PLOS ONE, 2021, 16 (06):